Influenza - behandeling met oseltamivir (Tamiflu)
Advices
| Priority | Medication | Remarks |
|---|---|---|
|
Medication: oseltamivir po 75mg 2dd 5 days |
| Priority | Medication | Remarks |
|---|---|---|
|
Medication: oseltamivir po 75mg 2dd 10 days |
Sources
-
https://umcg.zenya.work/portal/#/document/307abf6d-1d23-49e9-a65f-911d1a9df456
UMCG Influenzaprotocol
-
Pubmed.gov publication # 23204175
Muthuri et al., Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis, 2013.
-
Pubmed.gov publication # 16799169
Robson et al., The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2006.
-
Pubmed.gov publication # 23723457
South East Asia Infectious Disease Clinical Research Network, Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ, 2013.
-
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000402/WC500033106.pdf
European Medicines Agency, Oseltamivir product information
Antimicrobial resources
The following antimicrobial agents have been used in these recommendations:
External antimicrobial resources
Menu position
Metadata
Swab vid: G-211242.3
Updated: 01/06/2023 - 19:42
Status: Published
General comments
Zie voor diagnostiek en therapie van influenza UMCG Influenzaprotocol bij: Bron